Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BionimeTPE:4737 +0.53%65 EV-to-EBIT is -21.17 as of Aug. 21, 2026. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$54.04 (Fairly Valued). The stock has 7 warning signs investors should review. Among 473 Medical Devices & Instruments companies, Bionime ranks worse than 211416.28% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bionime's Enterprise Value is NT$6,650 Mil.
Bionime's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-314 Mil. Therefore, Bionime's EV-to-EBIT for today is -21.17.
The historical rank and industry rank for Bionime's EV-to-EBIT or its related term are showing as below:
TPE:4737'
s EV-to-EBIT Range Over the Past 10 Years
Min: -136.58 Med: 24.86 Max: 427.31
Current: -21.16
During the past 13 years, the highest EV-to-EBIT of Bionime was 427.31. The lowest was -136.58. And the median was 24.86.
TPE:4737's EV-to-EBIT is ranked worse than 100% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 18.87
vs TPE:4737: -21.16
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bionime's Enterprise Value for the quarter that ended in Jun. 2026 was NT$6,519 Mil.
Bionime's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-314 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime EV-to-EBIT Related Terms
Bionime EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bionime's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4737 vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Bionime's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionime EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionime's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bionime's EV-to-EBIT falls into.
Bionime's current Enterprise Value is NT$6,650 Mil.
Bionime's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-314 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime (TPE:4737) has a EV-to-EBIT of -21.17 as of Aug. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bionime and its competitors. According to the industry distribution chart, Bionime ranks #999999 out of 473 companies in the Medical Devices & Instruments industry.
Is Bionime's EV-to-EBIT too high?
Bionime's current EV-to-EBIT is -21.17. Based on the distribution chart, Bionime ranks #999999 out of 473 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bionime ranks #999999 out of 473 companies for EV-to-EBIT. This places Bionime in the lower half of its industry. The industry median EV-to-EBIT is 18.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.87, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bionime and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionime's current EV-to-EBIT is -21.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$54.04, compared to a current price of NT$57.30 — trading 6% above its estimated fair value. The current EV-to-EBIT is -21.17. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bionime (TPE:4737), the current EV-to-EBIT is -21.17 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionime (TPE:4737) Overvalued in 2026?
Based on GuruFocus' analysis, Bionime stock appears to be overvalued.
The current stock price of NT$57.30 is trading 6% above its estimated GF Value™ of NT$54.04.
GuruFocus considers Bionime to be Fairly Valued.
Key valuation signals for TPE:4737:
EV-to-EBIT: -21.17
GF Value™: NT$54.04 vs. price of NT$57.30 (6% above fair value)
No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score
Get the complete analysis for TPE:4737
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4737 has been successfully added to your 
